Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

McKinsey
Harvard Business School
Dow
Medtronic
AstraZeneca
Johnson and Johnson

Last Updated: May 19, 2022

CLINICAL TRIALS PROFILE FOR TRELSTAR


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Trelstar

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01467882 ↗ Efficacy, Safety, and Pharmacokinetics (PK) of Triptorelin 6-month Formulation in Patients With Central Precocious Puberty Completed Debiopharm International SA Phase 3 2012-04-01 The study will investigate the efficacy, safety and pharmacokinetics of triptorelin 22.5 mg 6-month formulation in 44 patients suffering from central precocious puberty. The total study duration per patient will be 12 months (48 weeks).
NCT02090114 ↗ RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistance (The RESTORE Study) Recruiting National Cancer Institute (NCI) Phase 2 2014-06-01 Single-arm, single site, open label study of the effects of parenteral testosterone followed by enzalutamide, abiraterone or castration-only therapy in men with metastatic CRPC who previously progressed on one of these forms of therapy. The study will enroll four cohorts of patients: men with metastatic CRPC who have progressed on enzalutamide (Cohort A; n=30); men with metastatic CRPC who have progressed on abiraterone acetate (Cohort B; n=30); men with metastatic CRPC who have progressed on first line castration-only therapy (Cohort C; n=30); men with metastatic CRPC with inactivating somatic or germline mutations in ≥2 of the genes TP53, PTEN, or RB1 (Cohort D; n=20).
NCT02090114 ↗ RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistance (The RESTORE Study) Recruiting Sidney Kimmel Comprehensive Cancer Center Phase 2 2014-06-01 Single-arm, single site, open label study of the effects of parenteral testosterone followed by enzalutamide, abiraterone or castration-only therapy in men with metastatic CRPC who previously progressed on one of these forms of therapy. The study will enroll four cohorts of patients: men with metastatic CRPC who have progressed on enzalutamide (Cohort A; n=30); men with metastatic CRPC who have progressed on abiraterone acetate (Cohort B; n=30); men with metastatic CRPC who have progressed on first line castration-only therapy (Cohort C; n=30); men with metastatic CRPC with inactivating somatic or germline mutations in ≥2 of the genes TP53, PTEN, or RB1 (Cohort D; n=20).
NCT02090114 ↗ RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistance (The RESTORE Study) Recruiting Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Phase 2 2014-06-01 Single-arm, single site, open label study of the effects of parenteral testosterone followed by enzalutamide, abiraterone or castration-only therapy in men with metastatic CRPC who previously progressed on one of these forms of therapy. The study will enroll four cohorts of patients: men with metastatic CRPC who have progressed on enzalutamide (Cohort A; n=30); men with metastatic CRPC who have progressed on abiraterone acetate (Cohort B; n=30); men with metastatic CRPC who have progressed on first line castration-only therapy (Cohort C; n=30); men with metastatic CRPC with inactivating somatic or germline mutations in ≥2 of the genes TP53, PTEN, or RB1 (Cohort D; n=20).
NCT02168062 ↗ Supportive Therapy in Androgen Deprivation Clinic in Improving Health Outcomes and Managing Side Effects in Patients With Prostate Cancer Terminated National Cancer Institute (NCI) Phase 2 2014-06-16 This pilot partially-randomized phase II trial studies how well Supportive Therapy in Androgen Deprivation (STAND) clinic works in improving health outcomes and managing side effects in patients with prostate cancer. Individualized counseling regarding exercise and dietary habits may help improve patient understanding, satisfaction, and overall lessen adverse impact on quality of life caused by androgen deprivation.
NCT02168062 ↗ Supportive Therapy in Androgen Deprivation Clinic in Improving Health Outcomes and Managing Side Effects in Patients With Prostate Cancer Terminated University of California, San Francisco Phase 2 2014-06-16 This pilot partially-randomized phase II trial studies how well Supportive Therapy in Androgen Deprivation (STAND) clinic works in improving health outcomes and managing side effects in patients with prostate cancer. Individualized counseling regarding exercise and dietary habits may help improve patient understanding, satisfaction, and overall lessen adverse impact on quality of life caused by androgen deprivation.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Trelstar

Condition Name

Condition Name for Trelstar
Intervention Trials
Prostate Cancer 5
Prostate Adenocarcinoma 2
Castration Resistant Metastatic Prostate Cancer 2
Castration-resistant Prostate Cancer Patients With Oligometastases 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Trelstar
Intervention Trials
Prostatic Neoplasms 9
Adenocarcinoma 2
Puberty, Precocious 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Trelstar

Trials by Country

Trials by Country for Trelstar
Location Trials
United States 44
Canada 5
Chile 1
Mexico 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Trelstar
Location Trials
California 6
Maryland 4
New Jersey 3
District of Columbia 3
Ohio 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Trelstar

Clinical Trial Phase

Clinical Trial Phase for Trelstar
Clinical Trial Phase Trials
Phase 4 1
Phase 3 1
Phase 2/Phase 3 1
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Trelstar
Clinical Trial Phase Trials
Recruiting 3
Active, not recruiting 2
Terminated 2
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Trelstar

Sponsor Name

Sponsor Name for Trelstar
Sponsor Trials
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 4
National Cancer Institute (NCI) 3
Sidney Kimmel Comprehensive Cancer Center 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Trelstar
Sponsor Trials
Other 11
Industry 4
NIH 3
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Dow
Boehringer Ingelheim
Merck
McKesson
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.